Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Re-Inventing R&D for Precision Medicine

Posted on May 22nd, 2017 by in Pharma R&D

Pills white paper

Precision medicine first emerged in the late ‘90s. But it was the completion of the Human Genome Project in 2003 that really opened up a world of opportunity in this area because it became possible to test patients for certain biomarkers that could help match patients to more tailored and appropriate treatments. That approach is really at the heart of precision medicine, which is all about using genetic information to treat the right patient at the right time with the right therapy.

This individualistic approach is exciting for patients who feel that rather than relying on a one-size-fits-all treatment, the therapies developed through precision medicine are more likely to be effective for their particular needs. And there’s no doubt that drug makers are eager to explore the possibilities that come with the increased availability of genetic data and analytical tools. In fact, according to the Tufts University Center for the Study of Drug Development, over 40% of the drugs currently in development have potential for personalized medicines – and that figure is projected to rise to some 70% over the next few years.

But, as the white paper “Precision Medicine: The New R&D Paradigm” attests, there are also challenges for drug developers and the industry as a whole as it moves away from the dogged search for big blockbuster drugs and into a focus on this new approach. That is because there isn’t yet a “tried and tested” business model for precision medicine that they can count on for success.

The industry is working hard to adapt, but more proactive measures are needed. Everything from university-based research initiatives to start-ups are certainly doing their part to advance precision medicine, but utilizing the right tools also plays a role. Using tools to focus research around disease mechanisms and molecular-level biology is important, as are developing tools that can better manage and analyze the deluge of personal data being generated.

Read the white paper now to learn more.


 

All opinions shared in this post are the author’s own.

R&D Solutions for Pharma & Life Sciences

We're happy to discuss your needs and show you how Elsevier's Solution can help.

Contact Sales